Taxotere

The chemotherapy drug Taxotere/Docetaxel was marketed to women as a more effective drug to treat breast cancer. Taxotere’s manufacturer failed to disclose what it knew to be a disfiguring side effect of the drug, namely permanent irreversible hair loss, to women in the United States. However, this side effect was disclosed to women in Europe since 2005. The FDA mandated a label change in the United States effective January 2016, but there are thousands of women who have taken this drug and not been advised of this consequence. There was and is an equally effective drug on the market that does not have this severe side effect.

The Taxotere Litigation Group acts as a platform for members in to discuss litigation and share research and expert information.

The Taxotere Litigation Group is sponsored by CAMG.